Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Lgenia Inc
Profile last edited on: 11/30/21      CAGE: 846B3      UEI: JFZLTK7QH945

Business Identifier: Therapeutics for debilitating diseases such as Tuberculosis, Malaria, and Alzheimer’s diseas
Year Founded
2018
First Award
2020
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

S Maple St
Fortville, IN 46040
   (316) 690-4885
   N/A
   www.lgenia.com
Location: Single
Congr. District: 06
County: Hancock

Public Profile

Lgenia Inc develops therapeutics for debilitating diseases such as Tuberculosis, Malaria, and Alzheimer’s disease. The company has partnerships with the TB Drug Accelerator, sponsored by the Bill and Melinda Gates Foundation, and the Indiana University School of Medicine. The firm is currently focused on studying the way the brain's immune system may contribute to Alzheimer's disease.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$225,343
Phase II Dollars
$0
Total Awarded
$225,343

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 1 NIH $225,343
Project Title: Novel QcrB Inhibitors for the Treatment of Tuberculosis

Key People / Management

  Philip Arthur Hipskind -- CEO and CSO

  Greg Durst -- Senior Portfolio Director

  Cynthia Jesudason -- Senior Portfolio Director

  Renhua Li -- Senior Portfolio Director

  Karen Lobb -- Senior Portfolio Director

  David Mendel -- Senior Portfolio Director

  Miles Siegel -- Senior Portfolio Director

Company News

Mar 02 2020
Indiana-based BioTech Collaborates with IU School of Medicine to Help Find a Cure for Alzheimer's